Mark Adams
Table of Contents show
About Priothera
Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.
Website: Learn more on Priothera’s website
Crunchbase: Follow on Crunchbase
[adace-ad id=”4426″]Series A – Priothera
| Amount Raised | 30000000 EUR |
| Announced Date | 2020-10-12 |
| Equity Only Funding | Yes |
| Organization Location | Dublin, Dublin, Ireland, Europe |
| Funding Status | Early Stage Venture |
| Number of Funding Rounds | 1 |
| Lead Investors | Earlybird Venture Capital, Fountain Healthcare Partners, HealthCap, Tekla Capital Management |
| Number of Investors | 4 |
| Number of Partner Investors | 4 |
